GERMANTOWN, Md., June 27,
2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq:
PGEN), a biopharmaceutical company specializing in the development
of innovative gene and cell therapies to improve the lives of
patients, today announced that Helen
Sabzevari, PhD, President and CEO of Precigen, will
participate in a virtual panel discussion titled, "Targeted T Cell
Therapies, Including Autologous CAR T, TCR and More" on
Thursday, June 30, 2022, at
1:00 PM ET at the Stifel 2022 Virtual
Cell Therapy Summit.
Event details can be found on Precigen's website in the Events
& Presentations section at
investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical
stage biopharmaceutical company advancing the next generation of
gene and cell therapies using precision technology to target the
most urgent and intractable diseases in our core therapeutic areas
of immuno-oncology, autoimmune disorders, and infectious diseases.
Our technologies enable us to find innovative solutions for
affordable biotherapeutics in a controlled manner. Precigen
operates as an innovation engine progressing a preclinical and
clinical pipeline of well-differentiated therapies toward clinical
proof-of-concept and commercialization. For more information about
Precigen, visit www.precigen.com or follow us on Twitter @Precigen,
LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release are
forward-looking statements. These forward-looking statements are
based upon the Company's current expectations and projections about
future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, discovery programs and related milestones, the promise of
the Company's portfolio of therapies, and in particular its CAR-T
and AdenoVerse therapies. Although management believes that the
plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties, including the
possibility that the timeline for the Company's clinical trials
might be impacted by the COVID-19 pandemic, and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. The Company has no
obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For further information on potential risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K
and subsequent reports filed with the Securities and Exchange
Commission.
Investor Contact:
Steven M. Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M. Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-the-stifel-2022-virtual-cell-therapy-summit-301576136.html
SOURCE Precigen, Inc.